跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KDR-2-2
首页
药物
KDR-2-2
KDR-2-2
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Antibodies to VEGF-C
US 7423125 B2
申请人: VEGENICS LTD
优先权: 2004
US
13 件公开
HUMAN ANTI-VEGFR-2/KDR ANTIBODIES
EP 3204423 A4
申请人: KADMON CORP LLC
优先权: 2014
CN
EP
US
WO
9 件公开
US 10023640 B2
申请人: KADMON CORP LLC
优先权: 2012
CN
US
5 件公开
Modifications of the VEGF Receptor-2 Protein and methods of use
US 6784285 B1
申请人: AGOURON PHARMA
优先权: 2000
US
7 件公开
COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER
EP 3168234 A1
申请人: MEDIMMUNE LTD
优先权: 2005
CN
EP
US
6 件公开
Chimeric human-type vascular endothelial cell growth factor
US 7405278 B2
申请人: SHIBUYA MASABUMI
优先权: 2000
US
4 件公开
DNA vaccine against proliferating endothelial cells and methods of use thereof
US 7094410 B2
申请人: SCRIPPS RESEARCH INST
优先权: 2002
US
4 件公开
TIMP3 as VEGF inhibitor
US 7183256 B2
申请人: CLEVELAND CLINIC FOUNDATION
优先权: 2004
US
4 件公开
5-substituted indazoles as kinase inhibitors
US 8648069 B2
申请人: AKRITOPOULOU-ZANZE IRINI
优先权: 2008
US
4 件公开
Methods and compositions as protein kinase inhibitors
US 7189729 B2
申请人: IRM LLC
优先权: 2003
CN
US
3 件公开
Compounds and compositions as protein kinase inhibitors
US 7846923 B2
申请人: IRM LLC
优先权: 2007
CN
US
3 件公开
第 1 / 6 页
上一页
下一页
药物
反馈